Ceria Therapeutics

Ceria Therapeutics is a private, pre-clinical stage biotech founded in 2021, headquartered in Cambridge, MA, with operations in Tucson, AZ, and San Juan, PR. The company's core innovation is a platform for delivering RNAi therapeutics via cerium oxide (a lanthanide) nanoparticles, initially targeting inflammatory conditions in wound care, critical care, and gastrointestinal care. Ceria employs a hybrid business model, advancing its own drug candidates while generating non-dilutive funding and validation through its manufacturing services and significant government grants from the NIH and Department of Defense. Its near-term strategy focuses on advancing lead programs for diabetic foot ulcers and acute lung injury toward clinical development.

Proprietary platform for synthesizing solid inorganic cerium oxide (lanthanide) nanoparticles conjugated with synthetic RNA (siRNA/miRNA) for targeted delivery and synergistic anti-inflammatory effects. Includes integrated capabilities in scalable GMP manufacturing, formulation, and aerosolization for inhaled therapeutics.

Competes with other RNAi delivery companies using lipid nanoparticles (e.g., Alnylam) and other modalities, as well as biotechs developing advanced wound healing biologics and cell therapies. Differentiation hinges on the unique anti-inflammatory properties of the cerium oxide nanoparticle carrier and its potential for localized and inhaled delivery.